Alan Ashworth

TL;DR: Evidence is provided that genetic variation in FGFR2 influences radiation-induced breast cancer risk by analyzing 2 independent case-control series from the United Kingdom and The Netherlands and finding rs1219648, which annotates theFGFR2 gene, was associated with risk.

TL;DR: The results suggest that fat loss by an individual can result in substantial decreases in postmenopausal estradiol and testosterone levels and provides support for weight management to lessen breast cancer risk.

TL;DR: For women with an established breast cancer whether their mutation directly influences baseline prognosis, the results of local surgical and radiation therapy, the benefits from adjuvant systemic therapy and whether selection or avoidance of particular systemic agents is guided by the presence of a BRCA1 or BRCa2 germline mutation are considered.

TL;DR: The current understanding of PARP inhibition as a treatment for metastatic breast cancer, evidence from clinical trials and addresses its future implications are discussed.

TL;DR: The nature of these genes suggests that loss of BRCA1 could lead to inappropriate proliferation, consistent with the high mitotic grade of B RCA1-associated tumours.